(Q28236480)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

title

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

10

Diederick E Grobbee

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1

Michiel L Bots

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

6

Charles H Tegeler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

3

Gregory W Evans

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Ward A Riley

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

James H Revkin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Charles L Shear

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

William T Duggan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Ralph M Vicari

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

John J Kastelein

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

RADIANCE 2 Investigators

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

English

0 references

publication date

1 July 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

volume

370

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

issue

9582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

page(s)

153-160

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

2 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Cardiovascular Health in Childhood: A Statement for Health Professionals From the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

World Heart Day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

HDL as a target in the treatment of atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Clinical practice. Low HDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

New insights into the regulation of HDL metabolism and reverse cholesterol transport

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Relation between cholesterol ester transfer protein activities and lipoprotein cholesterol in patients with hypercholesterolemia and combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Absence of cholesteryl ester transfer protein-mediated cholesteryl ester mass transfer from high-density lipoprotein to low-density lipoprotein particles is a major feature of combined hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

The failure of torcetrapib: was it the molecule or the mechanism?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Carotid intima-media thickness measurements in intervention studies: design options, progression rates, and sample size considerations: a point of view

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

A multiscale dynamic programming procedure for boundary detection in ultrasonic artery images.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Analysis strategies for serial multivariate ultrasonographic data that are incomplete

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

1996 Remington lecture: modeling multivariate longitudinal data that are incomplete

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Low-dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Two-year statin therapy does not alter the progression of intima-media thickness in patients with type 2 diabetes without manifest cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Fluvastatin and lifestyle modification for reduction of carotid intima-media thickness and left ventricular mass progression in drug-treated hypertensives

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind t

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Carotid Intima-Media Thickness and Antihypertensive Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Effect of torcetrapib on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

CETP inhibition in cardiovascular risk management: a critical appraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961088-5

7 January 2021

10.1016/S0140-6736(07)61088-5

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17630038%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017